Status:

RECRUITING

68Ga-PSMA PET in the Renal Cell Carcinoma

Lead Sponsor:

Xijing Hospital

Collaborating Sponsors:

Air Force Military Medical University, China

Shaanxi Provincial People's Hospital

Conditions:

Renal Cancer

Metastases

Eligibility:

All Genders

18-90 years

Phase:

NA

Brief Summary

The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced C...

Eligibility Criteria

Inclusion Criteria:

  • 2017 AJCC renal cell carcinoma TNM stage III, IV lesions;
  • In contrast-enhanced CT staging, suspicious metastases were found;
  • There were no known peripheral or central venous problems;
  • 68Ga PSMA PET / CT imaging can be performed within 6 weeks after the diagnosis of renal cell carcinoma;
  • Signed the informed consent form of voluntary participation in clinical trials.

Exclusion Criteria:

  • Age ≤ 18 years old;
  • Can't stand lying flat in PET / CT examination;
  • There are contraindications for 68Ga PSMA ligands;
  • In the past two years, there was a history of other malignant tumors, or according to the doctor's research judgment, complications may occur and affect the normal operation of the test;
  • Renal function is impaired or hemodialysis is in progress.

Key Trial Info

Start Date :

June 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2027

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT04987086

Start Date

June 1 2021

End Date

December 1 2027

Last Update

March 11 2026

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

The First Hospital of Lanzhou University

Lanzhou, Gansu, China

2

General Hospital of Ningxia Medical University

Yinchuan, Ningxia, China

3

Qinghai University Affiliated Hospital

Xining, Qinghai, China

4

Xijing Hospital

Xi'an, Shaan'xi, China, 710032